سعر اربيتوكس 100مجم/20 مل فيال 2025

Erbitux (cetuximab) 5 mg/mL solution for infusion, 100 mg/20 mL vial, listed in Egypt under Boehringer Ingelheim / Serono scientific office.

• EGFR-expressing, RAS wild-type metastatic colorectal cancer: in combination with irinotecan-based chemotherapy; first-line in combination with FOLFOX; or as a single agent after failure of oxaliplatin- and irinotecan-based therapy and in patients intolerant to irinotecan.Population: AdultsEuropean Medicines Agency (EPAR product information)
• BRAF V600E-mutant metastatic colorectal cancer: in combination with encorafenib (with or without FOLFOX, per the current SmPC).Population: AdultsEuropean Medicines Agency (EPAR product information)
• Squamous cell cancer of the head and neck: in combination with radiation therapy for locally advanced disease, or with platinum-based chemotherapy for recurrent and/or metastatic disease.Population: AdultsEuropean Medicines Agency (EPAR product information)

• Very common adverse reactions include skin reactions (in more than 80% of patients), hypomagnesaemia (more than 10%) and infusion-related reactions.International label, same product · European Medicines Agency (EPAR product information)

• Known severe (grade 3 or 4) hypersensitivity reactions to cetuximab.International label, same product · European Medicines Agency (EPAR product information)
• Combination with oxaliplatin-containing chemotherapy in patients with mutant RAS or unknown RAS status metastatic colorectal cancer.International label, same product · European Medicines Agency (EPAR product information)

• Severe infusion-related reactions including anaphylaxis may occur, sometimes fatal and possibly within minutes of the first infusion; risk is higher with pre-existing IgE antibodies to alpha-gal (e.g. red-meat or tick-bite allergy). Severe reactions require immediate and permanent discontinuation.International label, same product · European Medicines Agency (EPAR product information)
• Interstitial lung disease, including fatal cases, has been reported; interrupt treatment for suspected ILD and discontinue if confirmed.International label, same product · European Medicines Agency (EPAR product information)
• Skin reactions (mainly acneiform rash) are very common. For severe (grade ≥ 3) reactions interrupt treatment; resume at the same dose after a first occurrence, with a 20% dose reduction after a second and a 40% reduction after a third occurrence; discontinue permanently after a fourth occurrence or if not resolved to grade 2.International label, same product · European Medicines Agency (EPAR product information)

• Platinum-based chemotherapyCombination may increase the frequency of severe leukopenia or severe neutropenia and infectious complications compared with platinum-based chemotherapy alone.European Medicines Agency (EPAR product information)

• EGFR is involved in fetal development and IgG1 antibodies cross the placenta; use during pregnancy or in women not using adequate contraception only if the potential benefit justifies the potential risk to the fetus.International label, same product · European Medicines Agency (EPAR product information)
• It is recommended that women do not breastfeed during treatment with Erbitux and for 2 months after the last dose.International label, same product · European Medicines Agency (EPAR product information)

• Cetuximab: Binds specifically to EGFR, blocking binding of endogenous EGFR ligands and inhibiting receptor function; induces internalisation of EGFR and can target cytotoxic immune effector cells (EU Erbitux SmPC section 5.1).